Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21.

Wang Y, Fisher JC, Mathew R, Ou L, Otieno S, Sublet J, Xiao L, Chen J, Roussel MF, Kriwacki RW.

Nat Chem Biol. 2011 Apr;7(4):214-21. doi: 10.1038/nchembio.536. Epub 2011 Feb 27.

2.

Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity.

Kriwacki RW, Hengst L, Tennant L, Reed SI, Wright PE.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11504-9.

3.

p21: structure and functions associated with cyclin-CDK binding.

Ball KL.

Prog Cell Cycle Res. 1997;3:125-34. Review.

PMID:
9552411
4.

The role of the LH subdomain in the function of the Cip/Kip cyclin-dependent kinase regulators.

Otieno S, Grace CR, Kriwacki RW.

Biophys J. 2011 May 18;100(10):2486-94. doi: 10.1016/j.bpj.2011.04.014.

5.

Intrinsic protein flexibility in regulation of cell proliferation: advantages for signaling and opportunities for novel therapeutics.

Follis AV, Galea CA, Kriwacki RW.

Adv Exp Med Biol. 2012;725:27-49. doi: 10.1007/978-1-4614-0659-4_3. Review.

PMID:
22399317
6.

Cyclin-binding motifs are essential for the function of p21CIP1.

Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A.

Mol Cell Biol. 1996 Sep;16(9):4673-82.

7.

New functional activities for the p21 family of CDK inhibitors.

LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E.

Genes Dev. 1997 Apr 1;11(7):847-62.

8.

p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.

Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Dorée M, Messier H, Fotedar A.

Oncogene. 1996 May 16;12(10):2155-64.

PMID:
8668341
9.

Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.

Nakanishi M, Kagawa Y, Takahashi H, Matsushime H.

Leukemia. 1997 Apr;11 Suppl 3:356-7.

PMID:
9209388
10.

The amino terminus of Cdk2 binds p21.

Moskowitz NK, Borao FJ, Dardashti O, Cohen HD, Germino FJ.

Oncol Res. 1996;8(9):343-52.

PMID:
8979268
11.

Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.

Chen IT, Akamatsu M, Smith ML, Lung FD, Duba D, Roller PP, Fornace AJ Jr, O'Connor PM.

Oncogene. 1996 Feb 1;12(3):595-607.

PMID:
8637717
13.

Cell cycle regulation by the intrinsically disordered proteins p21 and p27.

Yoon MK, Mitrea DM, Ou L, Kriwacki RW.

Biochem Soc Trans. 2012 Oct;40(5):981-8. Review.

PMID:
22988851
14.

p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding.

Lacy ER, Filippov I, Lewis WS, Otieno S, Xiao L, Weiss S, Hengst L, Kriwacki RW.

Nat Struct Mol Biol. 2004 Apr;11(4):358-64. Epub 2004 Mar 14.

PMID:
15024385
15.

Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.

Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R.

Oncogene. 1999 May 27;18(21):3290-302.

16.
17.

Solution structure of p21(Waf1/Cip1/Sdi1) C-terminal domain bound to Cdk4.

Sung YH, Shin J, Shin J, Lee W.

J Biomol Struct Dyn. 2001 Dec;19(3):419-27.

PMID:
11790141
18.

Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1).

Hengst L, Göpfert U, Lashuel HA, Reed SI.

Genes Dev. 1998 Dec 15;12(24):3882-8.

20.

p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.

Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ.

Genes Dev. 1995 Mar 15;9(6):650-62.

Supplemental Content

Support Center